GLP-1s, PCOS, and insulin resistance: separating real from viral

What did @wellnessbyhaleigh actually say?

Honestly? Almost nothing medically verifiable. The transcript we have is lyrics or spoken-word poetry, something about bees, wind, and kids flying near the ocean. There are no direct medical claims in the words captured here.

The caption is a different story. There, the creator describes a personal experience with insulin resistance and PCOS, bloating, inflammation, fatigue, and feeling disconnected from her own body. She frames her story around the #glp1community hashtag, which strongly implies she is either using or advocating for GLP-1 receptor agonists like semaglutide or tirzepatide as part of her journey. But the video audio itself does not contain the health claims her caption sets up. That gap between caption and content matters when you are evaluating what someone is actually putting into the world.

We are rating this video primarily on the caption claims, because that is where the health-adjacent messaging lives.

Does the science back this up?

The connection between PCOS, insulin resistance, and the symptoms she describes is real and well-documented. The implied suggestion that GLP-1 medications can help is also supported by emerging research, though with meaningful caveats.

PCOS affects roughly 8 to 13 percent of reproductive-age women globally, and insulin resistance is present in 65 to 80 percent of PCOS cases regardless of body weight (Teede et al., 2018, Human Reproduction Update). The fatigue, bloating, and inflammatory symptoms the creator describes are consistent with what clinicians see in metabolic PCOS phenotypes. That part checks out.

On GLP-1s specifically: a 2023 randomized controlled trial by Jensterle et al. in Diabetes, Obesity and Metabolism found that semaglutide significantly reduced body weight, improved menstrual regularity, and lowered androgen levels in women with PCOS and obesity. A separate meta-analysis by Cena et al. (2020, Nutrients) showed liraglutide improved insulin sensitivity and reduced BMI in PCOS patients. So the implied treatment direction is not wrong. But these are supervised, clinical-dose interventions, not lifestyle supplements.

What did they get wrong (or right)?

She got the symptom picture right. PCOS-related insulin resistance genuinely does produce the cluster of complaints she lists, and it is underdiagnosed. Giving that experience a name and a community is not nothing.

What is missing is context. The hashtag #glp1community, combined with a PCOS and weight loss surgery framing, creates a strong implied endorsement of GLP-1 medications without any discussion of who these drugs are appropriate for, what the side effect profile looks like, or that they require medical supervision. That is not a minor omission.

The creator also uses the phrase "insulin resistance" and "inflammation" in ways that blur clinical definitions. Systemic inflammation in PCOS is real (González et al., 2012, Fertility and Sterility), but using it as a catch-all for feeling bad is looser than the science warrants. It feeds a trend where "inflammation" becomes a vague villain that sells products and programs rather than a specific, measurable physiological state.

• Symptom description: mostly accurate against clinical literature
• Implied GLP-1 endorsement: plausible but missing risk context
• "Inflammation" framing: oversimplified

What should you actually know?

If you have PCOS with insulin resistance, there are real, evidence-based options. Metformin remains a first-line pharmaceutical option with decades of data. GLP-1 receptor agonists are showing genuine promise in PCOS populations, but they are prescription medications with a real side effect profile including nausea, pancreatitis risk, and, in animal studies, thyroid c-cell tumors. They are not wellness supplements.

The weight loss surgery hashtags in this video (#wlsjourney, #wlscommunity) suggest the creator may have had bariatric surgery, which has its own distinct interaction with GLP-1 signaling. Bariatric patients should have GLP-1 medication decisions managed by a physician familiar with their surgical history, full stop.

One more thing worth saying plainly: videos like this, personal stories set to emotional music with chronic illness hashtags, can be genuinely helpful for people who feel isolated in their diagnosis. Visibility matters. But visibility without medical context can also funnel vulnerable people toward unregulated compounded peptides or unmonitored self-dosing. Those are not equivalent risks, and the community hashtag framing does not always make that distinction.